Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVAX is a good fit for your portfolio.
News
-
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
-
Shah Capital nominates two highly qualified independent director candidates for Novavax
-
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
-
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
-
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
-
Thinking about trading options or stock in Amazon, Eli Lilly, Altimmune, Novavax, or Snap?
Trading Information
- Previous Close Price
- $4.15
- Day Range
- $3.90–4.12
- 52-Week Range
- $3.53–11.36
- Bid/Ask
- $3.96 / $4.00
- Market Cap
- $552.81 Mil
- Volume/Avg
- 3.4 Mil / 7.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,992
- Website
- https://www.novavax.com
Comparables
Valuation
|
Metric
|
NVAX
|
DVAX
|
MRNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 18.38 | 40.16 |
Price/Book Value | — | 2.38 | 2.97 |
Price/Sales | 0.75 | 6.33 | 6.10 |
Price/Cash Flow | — | 37.35 | — |
Price/Earnings
NVAX
DVAX
MRNA
Financial Strength
|
Metric
|
NVAX
|
DVAX
|
MRNA
|
|---|---|---|---|
Quick Ratio | 0.53 | 12.65 | 3.21 |
Current Ratio | 0.70 | 13.81 | 3.42 |
Interest Coverage | −36.67 | −4.38 | −113.82 |
Quick Ratio
NVAX
DVAX
MRNA
Profitability
|
Metric
|
NVAX
|
DVAX
|
MRNA
|
|---|---|---|---|
Return on Assets (Normalized) | −26.26% | 3.72% | −20.12% |
Return on Equity (Normalized) | — | 6.14% | −26.85% |
Return on Invested Capital (Normalized) | — | 1.92% | −26.68% |
Return on Assets
NVAX
DVAX
MRNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vlkbsrkss | Bwhgn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ydffxmc | Wwxbr | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gzwxykwd | Nbbrd | $99.5 Bil | |
MRNA
| Moderna Inc | Gyddgjg | Jmydk | $38.8 Bil | |
ARGX
| argenx SE ADR | Fsvgdhdlp | Mpdr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wlflxrww | Dzyq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zfnjwcxzs | Ybnqcx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ngkmwjc | Cmrztyw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fbhmntdgl | Jpxcls | $12.5 Bil | |
INCY
| Incyte Corp | Gkkdptk | Flyhhl | $11.6 Bil |